View Older Stories
-
Oppenheimer Reiterates Outperform Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Lowered to $95 at Truist Securities
-
Boston Scientific (BSX) PT Lowered to $112 at Canaccord Genuity
-
Boston Scientific (BSX) PT Lowered to $110 at Stifel
-
Boston Scientific (BSX) PT Lowered to $110 at BTIG
-
Boston Scientific (BSX) PT Lowered to $105 at Piper Sandler, 'Buy The Dip'
-
Boston Scientific (BSX) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Evercore ISI Adds Boston Scientific (BSX) to TAP List
-
Mizuho on Boston Scientific (BSX): 'we do not foresee any FTC risk concerns'
-
Truist on Boston Scientific (BSX): 'PEN Acquisition To Strengthen BSX's Path Fwd'
-
Jefferies Downgrades Penumbra (PEN) to Hold
-
Needham Reiterates Buy Rating on Boston Scientific (BSX)
-
Wells Fargo Downgrades Penumbra (PEN) to Equal Weight
-
Morgan Stanley on Boston Scientific (BSX): 'Stock is looking too cheap and has clear catalysts'
-
Stifel on Boston Scientific (BSX): 'Compelling PEN Deal Adds to Growth and Future Margin Expansion'
-
William Blair Downgrades Penumbra (PEN) to Market Perform
-
Penumbra surges on news of $14.5 billion Boston Scientific buyout, BSX down
-
Boston Scientific (BSX) Removed from Citi Focus List
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
UBS on Boston Scientific (BSX): Risk/Reward Into 2026 Skewed to the Upside
-
TD Cowen on Boston Scientific (BSX): 'We See Sustained Momentum Driving Multiple Re-Expansion'
-
Raymond James Publishes 31st Annual Analyst Best Picks List for 2026
-
Nephron Downgrades Boston Scientific (BSX) to Hold
-
These 2 MedTech companies can continue to gain EP share in 2026: BofA
-
This medical technology firm has a "best-in-class portfolio," UBS says
-
Boston Scientific director Sununu will not seek re-election in 2026
-
Canaccord Genuity Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $140 at UBS
-
Boston Scientific (BSX) PT Raised to $130 at Leerink Partners
-
Boston Scientific (BSX) PT Raised to $124 at Goldman Sachs
-
Stifel on Boston Scientific (BSX): 'We expect especially positive growth contributions from Watchman and Electrophysiology'
-
BTIG: 'we think BSX remains a name to own'
-
Boston Scientific (BSX) PT Raised to $113 at Evercore ISI
-
Boston Scientific (BSX) Tops Q3 EPS by 4c; beats on guidance
-
TD Cowen on Boston Scientific (BSX): 'remains our top pick'
-
Evercore Adds Names to TAP Lists
-
Piper Sandler on Boston Scientific (BSX): 'Why Didn't Shares of BSX Respond Better to Its Analyst Day?'
-
Erste Group Downgrades Boston Scientific (BSX) to Hold
-
TD Cowen on Boston Scientific (BSX): 'Today's Portfolio Review Should Reinvigorate the Bull Case'
-
RBC Capital on Boston Scientific (BSX): 'We See the I-Day as a Clearing Event'
-
Stifel Reiterates Buy Rating on Boston Scientific (BSX)
-
Piper Sandler on Boston Scientific (BSX): 'Still Our Favorite LC Diversified'
-
Bernstein Calls Boston Scientific (BSX) a 'Great Stock Story'
-
Oppenheimer Reiterates Outperform Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $129 at Truist Securities
-
Boston Scientific (BSX) PT Raised to $132 at Canaccord Genuity
-
Boston Scientific (BSX) PT Raised to $132 at BTIG
-
RBC Capital on Boston Scientific (BSX): 'Bullish on Next Leg of Growth'

